Safety of Canephron® N for the treatment of urinary tract infections in the first trimester of pregnancy

Abstract

Background: Urinary tract infections (UTIs) are among the most commonly occurring bacterial infections, particularly in pregnant women. Canephron® N (Bionorica, Germany) is a phytotherapeutic medicinal product that has pleiotrophic effects on the urinary system, including diuretic, spasmolytic, anti-inflammatory, antimicrobial and nephroprotective effects. The purpose of this retrospective study was to assess the safety of Canephron® N when used in the first trimester of pregnancy for the treatment of UTIs. Methods: This was a retrospective, multi-center study that evaluated the effects of Canephron® N in 384 women who had used the herbal drug during the first trimester of pregnancy (between 2004 and 2009), and whose pregnancies ended in live births. The endpoints assessed in this study were the presence of congenital defects in the newborn. Results: There were no significant differences in the incidence of congenital malformations in newborns whose mothers had taken Canephron® N in the first trimester of pregnancy, compared to the national statistical data for the Kiev population during the same period. The majority of newborns (>65 %) whose mothers had received Canephron® N during the first trimester of pregnancy had Apgar scores of 8 or above, indicating an excellent safety status. Conclusions:The results from our study indicate that the use of Canephron® N during the first trimester of pregnancy was not associated with any teratogenic, embryotoxic or fetotoxic effects on the fetus.

A systematic review of non-antibiotic measures for the prevention of urinary tract infections in pregnancy

“…A review by Naber et al [ 38 ] assessing the efficacy of Canephron® N suggests that there might be some benefit from its use in pregnant women because it included evidence from additional studies which have not been discussed here as they were conducted in pregnant women with co-morbidities and so did not meet the inclusion criteria of this review. It is worth noting that the safety of Canephron® N in pregnancy has been established [ 39 , 40 ] but in order to make an evidence based recommendation, its efficacy needs to be confirmed by a randomised controlled trial.…”

Examination of Complementary Medicine for Treating Urinary Tract Infections Among Pregnant Women and Children

“…A few clinical studies investigated the effects of Canephron® N on the rates of congenital malformations of children born from mothers receiving the remedy during first, second, or third trimesters of pregnancy ( Repina et al, 2006 ; Medved and Islamova 2009 ; Medved 2015 ). It appears that Canephron® N treatment in pregnant women did not result in any teratogenic, embryotoxic effects or defects of infant development.…”

Nephroprotective Effect of the Herbal Composition BNO 2103 in Rats with Renal Failure

“…У дослідженні серед пацієнтів зі стеатогепатитом із ХХН I-II стадії було підтверджено вірогідне покращення видільної функції нирок на фоні комбінованого застосування BNO 2103 і S-аденозилметіоніну [13]. Також була доведена можливість безпечного використання препарату у вагітних [14][15][16] і при алергії на антибактеріальні препарати [17]. У той самий час на сьогодні кількість сучасних досліджень недостатня для формування переконливої доказової бази, для обґрунтування застосування BNO 2103 при ХХН.…”